- Home
- SGMT vs PHIO Comparison
SGMT vs PHIO Comparison
Compare SGMT & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- PHIO
- Stock Information
- Founded
- SGMT 2006
- PHIO 2011
- Country
- SGMT United States
- PHIO United States
- Employees
- SGMT N/A
- PHIO N/A
- Industry
- SGMT
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- SGMT
- PHIO Health Care
- Exchange
- SGMT Nasdaq
- PHIO Nasdaq
- Market Cap
- SGMT 71.2M
- PHIO N/A
- IPO Year
- SGMT 2023
- PHIO N/A
- Fundamental
- Price
- SGMT $3.34
- PHIO $1.78
- Analyst Decision
- SGMT Strong Buy
- PHIO Strong Buy
- Analyst Count
- SGMT 6
- PHIO 1
- Target Price
- SGMT $25.67
- PHIO $4.00
- AVG Volume (30 Days)
- SGMT 553.0K
- PHIO 1.8M
- Earning Date
- SGMT 05-08-2025
- PHIO 05-20-2025
- Dividend Yield
- SGMT N/A
- PHIO N/A
- EPS Growth
- SGMT N/A
- PHIO N/A
- EPS
- SGMT N/A
- PHIO N/A
- Revenue
- SGMT N/A
- PHIO N/A
- Revenue This Year
- SGMT N/A
- PHIO N/A
- Revenue Next Year
- SGMT N/A
- PHIO N/A
- P/E Ratio
- SGMT N/A
- PHIO N/A
- Revenue Growth
- SGMT N/A
- PHIO N/A
- 52 Week Low
- SGMT $1.73
- PHIO $0.97
- 52 Week High
- SGMT $7.38
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- SGMT 53.97
- PHIO 47.39
- Support Level
- SGMT $3.19
- PHIO $1.68
- Resistance Level
- SGMT $3.45
- PHIO $2.16
- Average True Range (ATR)
- SGMT 0.31
- PHIO 0.24
- MACD
- SGMT 0.05
- PHIO -0.06
- Stochastic Oscillator
- SGMT 55.52
- PHIO 8.54
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.